What's Happening?
Moderna, Inc. has been the focus of several analyst reports following its recent earnings announcement and ongoing cost-cutting strategies. UBS has highlighted potential upside for 2026 due to Moderna's
expense discipline and pipeline developments. Redburn Atlantic has reduced its price target for Moderna from $53 to $36, maintaining a neutral rating. Bernstein has reiterated a market perform stance with a $25 price target, emphasizing the importance of cost reductions to avoid external capital needs. Moderna's stock saw an increase during the U.S. trading session as these analyst comments were released.
Why It's Important?
The analyst reactions are significant as they reflect Wall Street's assessment of Moderna's strategic direction, particularly in light of its Q3 2025 results, which showed a narrower-than-expected loss and a tightened sales guidance. The company's aggressive cost controls are crucial as demand for COVID and RSV vaccines remains subdued. These measures are part of a broader plan to achieve cash breakeven by 2028, a timeline closely monitored by investors. The analyst reports provide insights into how Moderna's financial strategies and pipeline developments are perceived by the market.
What's Next?
Moderna's future stock movements may be influenced by regulatory clarity on its COVID/flu combination vaccine, potential RSV label expansions, and progress in its oncology pipeline, particularly the individualized neoantigen therapy mRNA-4157. The broader mRNA ecosystem is also meeting at the International mRNA Health Conference, which could impact sentiment around mRNA technologies, including Moderna's programs.
